Fig. 2

Phenotype changes induced by EGFRxCD3 BsAb and OVs. A Titration of EGFRxCD3 BsAb by the activation (CD69 expression) of CD4 + and CD8 + T cells (n = 3). B Experimental design. C CD4/CD8 ratio of T cells after 48 h incubation with target cells in different conditions: presence or absence of BsAb and different A375 tumor cell infections (v: vehicle, ONCOS-102 or ONCOS-204). D Percentage change of expression of CD69, GITR and OX40 in CD4 + (white) and CD8 + (blue) T cells upon exposure to infected A375 tumor cells. E Percentage change of expression of LAG-3 and PD-1 in CD4 + (white) and CD8 + (blue) upon exposure to infected A375 tumor cells. F CD69, GITR and OX40 co-expression analysis in CD4 + and CD8 + T cells in different conditions: non-infected tumor cells (no virus) vs. tumor cells infected with vehicle or ONCOS-102 or ONCOS-204. G LAG-3 and PD-1 co-expression analysis in CD4 + and CD8 + T in different conditions: non-infected tumor cells (no virus) vs. tumor cells infected with vehicle or ONCOS-102 or ONCOS-204. Friedman test with Dunn’s correction was used (C–G) to compare groups of paired samples exposed to different conditions (n = 8). *p < 0.05, **p < 0.01, ***p < 0.001. Medians are represented